Comment from Nia Heyward

Comment on FDA Draft Guidance: Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development I support the FDA’s draft guidance on long-term clinical neurodevelopmental safety studies in neonatal product development because it recognizes that evaluating safety in neonates requires more than assessing immediate outcomes. The neonatal period is characterized by rapid brain growth and development, meaning that some adverse effects of drugs, biologics, and medical devices may not become evident until months or years later. I agree with the guidance’s recommendation that sponsors determine the need for long-term follow-up by considering patient-specific, disease-specific, and product-specific factors. Another strength of the guidance is its emphasis on family engagement throughout long-term follow-up. Families of NICU graduates often face transportation challenges, financial burdens, and frequent healthcare appointments, making continued participation in research difficult. Strategies such as obtaining consent early, maintaining communication with families, and minimizing participant burden can improve retention and increase the quality of long-term safety data. One recommendation I would make is to continue encouraging standardized neurodevelopmental outcome measures across neonatal clinical trials. Using validated assessment tools to evaluate cognition, language, motor skills, behavior, sensory function, and social development would strengthen comparisons between studies and improve the evidence available to clinicians caring for neonates. Overall, I believe this guidance provides a practical framework for improving the long-term evaluation of medical products used in newborns. Continued emphasis on long-term neurodevelopmental follow-up will help ensure that therapies are not only effective during hospitalization but also support healthy development throughout childhood. References Committee on Fetus and Newborn. (2010). Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics, 126(4), 800–808. Food and Drug Administration. (2024). Considerations for long-term clinical neurodevelopmental safety studies in neonatal product development: Guidance for industry. U.S. Department of Health and Human Services. Spittle, A., Orton, J., Anderson, P. J., Boyd, R., & Doyle, L. W. (2015). Early developmental intervention programmes provided post-hospital discharge to prevent motor and cognitive impairment in preterm infants. Cochrane Database of Systematic Reviews, (11), CD005495.